Objective:To evaluate the efficacy and safety of azacitidine(AZA)combined with HAG regimen in the treatment of newly diagnosed elderly acute myeloid leukemia(AML)patients.Methods:Twenty-four newly diagnosed elderly AML patients ineligible for intensive chemotherapy from September 2021 to September 2023 in the Sinopharm Tongmei General hospital were prospectively enrolled in this study.They were randomly divided into treatment group and control group.The treatment group was treated with azacytidine combined with low-dose HAG regimen(AZA-HAG),while the control group was treated with decitabine combined with CAG regimen(DAC-CAG).The therapeu-tic effects of the two groups were evaluated.Results:After one course of treatment,the total remission rate(OR)of treatment group was 66.7%,and that of control group was 58.3%,and there was no significant difference between the two groups(P＞0.05).The average survival time of treatment group was 11.0 months,and that of control group was 9.5 months.The overall survival(OS)was no significant difference between the two groups(P＞0.05).In the treat-ment group,there were 7 cases(58.3%)with 4-degree bone marrow suppression,and the recovery days of bone mar-row suppression were(13.50±2.84)d;In the control group,all 12 cases suffered from 4-degree bone marrow sup-pression(100.0%),and the days of recovery from bone marrow suppression were(17.67±2.23)d,and the difference was statistically significant(P＜0.05).Conclusion:Azacitidine combined with low-dose HAG regimen is effective in the treatment of newly diagnosed elderly AML patients who are not eligible for intensive chemotherapy,and it is safe and cost-effective.
维普
万方数据